Sign in
Taking people in United StatesPhase 2

Exercise and beetroot juice for leg pain from peripheral artery disease

Tests supervised walking exercise, with or without beetroot juice, in people with peripheral artery disease.

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the 2 sites
Trial code
Registry title
Response to Exercise and Nitric Oxide in PAD
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
23 Jan 2025
Expected to end
1 Oct 2029
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Supervised Treadmill Exercise
  • Attention Control
  • Nitrate-Rich Beetroot Juice + supervised exercise therapy
  • Placebo + supervised exercise therapy
Record updated
27 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 or older with peripheral artery disease (PAD), meaning narrowed leg arteries. It tests supervised treadmill exercise and, for some people, nitrate-rich beetroot juice.

Age
50 Years and older
Sex
All
Disease stage
PAD shown by an ABI (ankle-arm blood pressure ratio) of 0.90 or less, by vascular lab tests (such as toe brachial pressure of 0.70 or less), or by imaging showing at least 70% narrowing of a leg artery. People with an ABI above 0.90 and below 1.00 can also join if their ABI drops 20% or more after a heel-rise test. Severe limb-threatening ischemia (ABI less than 0.40 with pain at rest) cannot join.
Earlier treatment
No supervised treadmill exercise program in the previous three months. No major surgery, coronary or leg revascularization (procedure to restore blood flow) in the previous three months. No clinical trial in the previous three months. Must stop beetroot juice, oral nitrate or nitrite, or beetroot supplements for 14 days before baseline testing.

Main reasons for not taking part

  • Above- or below-knee amputation, or needing a wheelchair or walker
  • Walking limited by a condition other than PAD, or foot ulcer on the bottom of the foot
  • Kidney failure treated with hemodialysis
  • Major illness, such as lung disease needing oxygen, Parkinson's disease, or cancer treated in the past two years
  • Dementia or MMSE score less than 23, unstable angina, or not speaking English

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • An ABI less than or equal to 0.90 at baseline
  • Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities
  • An ABI of more than 0.90 and less than 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test

Who cannot take part

  • End-stage kidney disease (ESKD) that is treated with hemodialysis
  • Planned major surgery, coronary or leg revascularization during the next six months
  • Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
  • Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.]
  • Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and/or unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 14 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial
  • Currently consuming one cup or more of beets daily. Participants will be asked to discontinue beet ingestion of one cup or more of beets for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial
  • Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.] Participants in a study that involved up to three single doses of nitrate-rich beetroot juice administered on separate days may participate if a month has passed since their last dose of nitrate-rich beetroot juice
  • Participation in a supervised treadmill exercise program in previous three months or planning to begin a supervised treadmill exercise program in the next six months
  • Walking is limited by a condition other than PAD
  • Current foot ulcer on bottom of foot
  • Failure to complete study-run
  • Mini-Mental Status Examination (MMSE) score less than 23 or dementia. If the MMSE is less than 23 and the Principal Investigator evaluation determines that the lower score is related to language barriers or education level, the Principal Investigator has discretion to allow a participant with MMSE less than 23 to participate, as appropriate. Dementia with sufficient impairment to prevent full engagement in all aspects of the trial will be an exclusion per the investigator's discretion
  • Allergy to beetroot juice
  • Unstable angina
  • Visual impairment that limits walking ability
  • History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial
  • Abnormal baseline stress test without subsequent clearance for exercise by physician
  • Above- or below-knee amputation
  • Limb-threatening ischemia defined as an ABI less than 0.40 with symptoms of rest pain
  • Wheelchair confinement or requiring a walker to ambulate
  • Unwilling to accept randomization into either group (supervised exercise or attention control)
  • Planning to engage in new walking exercise outside of the study or unwilling to refrain from new walking exercise activity during the trial
  • Already exercising at a level consistent with exercise intervention, using investigator discretion
  • Non-English speaking. The RESIST PAD interventions are delivered by interventionists who do not speak non-English languages. The integrity of the clinical trial requires clear and effective communication for data collection and intervention delivery. The trial does not have staff members who are fluent in non-English languages nor does it have the ability to translate all study materials into other languages
  • Baseline blood pressure less than 100/45
  • In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant

Where in United States

  • Northwestern University Feinberg School of MedicineChicago, United StatesContact: Kathryn DomanchukTaking people
  • University of ChicagoChicago, United StatesContact: Tamar Polonsky, MDNot yet recruiting

About the trial

What the trial wants to find out

RESIST PAD is a randomized trial of 200 PAD patients to establish: 1) whether a 12-week exercise intervention significantly increases Δ nitrite at 12-week follow-up, compared to control; 2) whether exercise "responders" have greater Δ nitrite increases compared to "non-responders"; 3) among non-responders, whether supplementing exercise with nitrate-rich beetroot juice between weeks 13-24 increases Δ nitrite and improves 6-minute walk at 24-week follow-up.

The 4 groups in the trial

  • Supervised Treadmill ExerciseTreatment being tested

    This group will be participating in supervised treadmill exercise for 12 weeks. Participants will walk for exercise on a treadmill 3 times per week at a center while supervised by healthcare personnel.

  • Attention Control GroupSham treatment, for comparison

    This group will attend weekly one-hour educational sessions either on Zoom or in-person for 12 weeks. These sessions are on topics of interest to the typical PAD patient and may be led by study staff, physicians, or other health care workers.

    Treatment: Attention Control

  • Exercise Supplementation with Nitrate-Rich Beetroot JuiceTreatment being tested

    This group for "non-responders" will receive supervised exercise supplementation with nitrate-rich beetroot juice for an additional 12 weeks.

    Treatment: Nitrate-Rich Beetroot Juice + supervised exercise therapy

  • Exercise Supplementation with Placebo Beetroot JuicePlacebo, for comparison

    This group for "non-responders" will received supervised exercise supplementation with placebo beetroot juice for the additional 12 weeks.

    Treatment: Placebo + supervised exercise therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Response to Exercise and Nitric Oxide in Peripheral Artery Disease: The RESIST PAD Trial
Plain-language title
Exercise and beetroot juice for leg pain from peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Publications
Record updated
27 July 2026